SCHEMBL6931077

SCHEMBL6931077

C=CCOc1ccc(C=O)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.44
CA1 P00915 5/20 0.44
CA9 Q16790 5/20 0.44
HPGD P15428 3/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 2/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
MAOB P27338 1/20 0.41
AGER Q15109 1/20 0.41
KAT6A Q92794 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22779337 0.87 CA12 (0.44) CA12CA1CA9HPGDALDH1A1
SCHEMBL22322029 0.83 ALDH1A1 (0.37) HPGDALDH1A1MAPTSMN1; SMN2MAOB
SCHEMBL27957723 0.82 MAPT (0.50) CA12CA1CA9HPGDALDH1A1
SCHEMBL1520406 0.81 ALDH1A1 (0.47) CA12CA1CA9HPGDALDH1A1
SCHEMBL7046014 0.80 TDP1 (0.47) CA12CA1CA9HPGDALDH1A1
SCHEMBL28011522 0.80 CA12 (0.46) CA12CA1CA9HPGDALDH1A1
SCHEMBL4501693 0.80 ALDH1A1 (0.54) CA12CA1CA9HPGDALDH1A1
SCHEMBL6561561 0.80 TRIM24 (0.57) CA12CA1CA9HPGDALDH1A1
SCHEMBL3170130 0.79 NQO1 (0.45) HPGDALDH1A1GAAMAPTLMNA
SCHEMBL8390279 0.79 MIF (0.54) CA12CA1CA9HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008099020-A1 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTENES USEFUL AS HEPATITIS C VIRUS INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-08-21 WO disclosed
EP-1363876-A1 GLUCOCORTICOID RECEPTOR MODULATORS Abbott Laboratories (US) 2003-11-26 EP disclosed
US-6583180-B2 Antidiabetic agents ABBOTT LABORATORIES 2003-06-24 US disclosed
US-20020156311-A1 Glucocorticoid receptor modulators KARO BIO AB (SE) 2002-10-24 US disclosed
WO-2002064550-A1 GLUCOCORTICOID RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156311-A1 Glucocorticoid receptor modulators NR3C1, NR5A1, NR3C2 CA12 4241/4885CA1 3999/4885CA9 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.